Roth Capital Has Pessimistic Outlook of CELZ FY2027 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Roth Capital reduced their FY2027 EPS estimates for shares of Creative Medical Technology in a note issued to investors on Friday, March 21st. Roth Capital analyst J. Aschoff now expects that the company will earn $3.00 per share for the year, down from their prior estimate of $3.26. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share.

Creative Medical Technology Stock Down 8.3 %

Shares of NASDAQ CELZ opened at $2.64 on Monday. Creative Medical Technology has a twelve month low of $1.96 and a twelve month high of $6.90. The company has a market cap of $4.61 million, a PE ratio of -0.69 and a beta of 1.70. The business’s 50 day moving average price is $3.77 and its two-hundred day moving average price is $3.26.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC bought a new position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned 0.59% of Creative Medical Technology as of its most recent filing with the SEC. Institutional investors and hedge funds own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.